ESMO need-to-know: Imfinzi wows, Incyte unveils, plus Lilly, Merck, BMS and more

11th September 2017 Uncategorised 0

The European Society for Medical Oncology’s annual Congress brought in a record 23,000 people for a research slate that included some truly late-breaking data, plus hotly anticipated numbers from trials such as AstraZeneca’s Pacific, a win for its immuno-oncology med Imfinzi. Here’s your need-to-know, with updates still to come.

More: ESMO need-to-know: Imfinzi wows, Incyte unveils, plus Lilly, Merck, BMS and more
Source: fierce